Dr. Kaytlin Krutsch leads the work at the InfantRisk Center at Texas Tech University Health Sciences Center in Amarillo, the center Dr. Thomas Hale founded, and she has now worked on three editions of Hale’s Medications & Mothers’ Milk, including the 23rd. She came to this work as a pharmacist with degrees in nutrition and business and board certification in pharmacotherapy, and she still remembers the mother she couldn’t answer as a clinician. That moment, and becoming a mother herself the year she met Dr. Hale, changed the direction of her career. We start with the origin story: a toxicologist in a pediatrics department, neonatologists who wanted to give NICU babies their mothers’ milk, a book that began as a floppy disk, and a call center that exists because people would not stop calling Dr. Hale. Then we get practical. Dr. Krutsch explains which of the three InfantRisk apps lactation professionals should actually be using, how she decides what makes it into a book when her database holds about 4,000 drugs, and why an L2 rating for one situation does not answer a question about a completely different one. The heart of the conversation is clinical reasoning. How drugs cross the lactocyte barrier, why relative infant dose is the first thing she looks at, why maternal dose matters more than most of us account for, and where half-life and timing fit in. We also cover the questions I hear constantly: GLP-1 medications, Adderall, caffeine, oxycodone after cesarean birth, and cannabis, including a bedside milk test her team is developing. What You’ll LearnHow a toxicologist, a new NICU, and a stack of floppy disks became Hale’s Medications & Mothers’ Milk and the InfantRisk call centerThe difference between the Hale’s, InfantRisk HCP, and MommyMeds apps, and why Dr. Krutsch would rather lactation consultants not rely on MommyMedsThe sobering numbers: how many drugs have milk-level data versus actual infant outcome dataWhy roughly half of InfantRisk calls now come from healthcare providers, and what they’re really asking (“What do other people do?”)Why a 10 to 15 woman lactation study is considered solid, and why InfantRisk prioritizes going from zero data to some dataWhat the NICHD-funded CUDDLE study added for oxycodone, and why oxycodone came off cesarean care plans for reasons that have nothing to do with milkA clinician’s tour of tight junctions, protein binding, volume of distribution, and the memantine case that burned her on transportersWhy relative infant dose is her first stop, where the 10% threshold came from, and when 10% is still not okayThe Adderall finding that changes counseling: as maternal dose goes up, milk levels go up in a linear way, an eightfold difference across mothers in her studyWhy lowering a mother’s dose is not automatically safer for the baby, especially for ADHD and depressionImmediate-release versus extended-release, and when timing feeds around a peak is realistic (and when it isn’t three weeks postpartum)Her hypothesis about caffeine in milk, infant caffeine withdrawal, and her pet peeve: “pregnancy and breastfeeding” are not the same thingWhat her research showed about semaglutide in milk, why she recommends injectable GLP-1s only, and why nutrients worry her more than the drugHow to read L-levels as quick guides instead of rules, using propofol (procedural vs. an ICU drip) as the exampleWhy polypharmacy is the next big unanswered question, and when to just call InfantRiskWhy cannabis is her least favorite question, and how a bedside THC milk test could support harm reduction without telling mothers what to decide Chapters00:00 — Introduction03:14 — Welcome, Dr. Krutsch03:20 — The InfantRisk Center and how Dr. Hale started it05:33 — From floppy disk to the 23rd edition of Hale’s06:33 — How the InfantRisk call center began07:55 — The three apps: Hale’s, InfantRisk HCP, and MommyMeds10:56 — What brought Dr. Krutsch to this work14:42 — Inferring when there’s no data15:50 — 4,000 drugs, and how few have infant data16:45 — Who calls InfantRisk now, and why case reports matter18:53 — Global resources: LactMed, e-lactancia, and domperidone23:04 — Who studies drugs in milk, and why InfantRisk chases the unanswered question25:32 — Oxycodone, the CUDDLE study, and cesarean care plans29:36 — How drugs get chosen for the book (and a first-in-class pain drug)31:20 — Predicting milk transfer: tight junctions, protein binding, volume of distribution36:45 — What clinicians actually need: relative infant dose38:42 — Adderall, maternal dose, and treating the mother42:31 — Half-life, formulations, and timing feeds44:02 — Caffeine in milk and the 200 mg question46:32 — Maternal health conditions and spotting patterns49:41 — GLP-1 medications and maternal nutrition58:58 — How to use L-levels (and when not to)1:02:02 — Polypharmacy and when to call InfantRisk1:03:28 — The future of Hale’s and building a team1:05:56 — How purchases and donations fund the research1:07:52 — Cannabis, harm reduction, and a bedside THC milk test1:17:22 — Where to find Dr. Krutsch and InfantRisk Resources MentionedInfantRisk Center (home base, call center, and apps): https://www.infantrisk.comInfantRisk call center (free for families and providers): 1-806-352-2519, 8 AM to 3 PM CentralHale’s Medications & Mothers’ Milk online (HalesMeds): https://www.halesmeds.comHale’s Medications & Mothers’ Milk app (HalesMeds): https://apps.apple.com/us/app/halesmeds/id1400067173 | Android: https://play.google.com/store/apps/details?id=com.hltcorp.medsmilkInfantRisk HCP app: https://apps.apple.com/us/app/infantrisk-hcp/id449136121MommyMeds app (for families): https://apps.apple.com/us/app/mommymeds/id669222544LactMed (NIH drugs and lactation database): https://www.ncbi.nlm.nih.gov/books/NBK501922/e-lactancia (Spain): https://www.e-lactancia.orgHow to report an adverse event to the FDA (MedWatch): https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-programSupport InfantRisk research through Texas Tech University Health Sciences Center: https://infantrisk.com/donate (choose “Search for Specific Fund” and search “InfantRisk Center”)My earlier episode, Rethinking the Lactating Breast with Dr. Donna Geddes: https://podcasts.apple.com/us/podcast/rethinking-the-lactating-breast-with-dr-donna-geddes/id1764781863?i=1000789967745Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J., & Krutsch, K. (2024). Subcutaneous semaglutide during breastfeeding: Infant safety regarding drug transfer into human milk. Nutrients, 16(17), 2886. https://doi.org/10.3390/nu16172886Research referenced in conversation: the NICHD-funded CUDDLE study (oxycodone in milk and infant plasma), InfantRisk’s unpublished amphetamine dose-response data, ACOG’s updated guidance on cannabis use and breastfeeding Sources: InfantRisk CenterInfantRisk FAQInfantRisk DonateHalesMeds on the App StoreHalesMeds Android listing (AppFollow)InfantRisk HCP on the App StoreMommyMeds on the App StoreBehind the Latch on Apple Podcasts Music: a href="https://open.spotify.com/track/5Q7WMVIaE9Kos3eMHUvvow" rel="noopener...